Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study [Yahoo! Finance]
Onconetix, Inc. (ONCO)
Company Research
Source: Yahoo! Finance
cancer survival rates through early detection, announces today that the company has successfully developed accurate and precise assays to measure targeted proteins for its next-generation test. As announced in November 2023 , Immunovia successfully finalized a discovery study that evaluated nearly 3,000 proteins to identify 15 promising protein biomarkers for its next-generation test to detect early-stage pancreatic cancer. As the next milestone in developing its next-generation test Immunovia, in collaboration with the company's research and development partner Proteomedix (an Onconetix company), has developed accurate and reliable assays to measure the most promising proteins identified in the discovery study to move forward to a model-development study. The newly developed assays leverage commercial reagents and an automated, high-throughput ELISA testing platform. By moving from the proprietary IMMray platform used for Immunovia's prior test, IMMray PanCan-d, to the widely u
Show less
Read more
Impact Snapshot
Event Time:
ONCO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCO alerts
High impacting Onconetix, Inc. news events
Weekly update
A roundup of the hottest topics
ONCO
News
- UT Health San Antonio to lead $11 million, NIH-funded study of a first-ever oral chlamydia vaccine [Yahoo! Finance]Yahoo! Finance
- Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director [Yahoo! Finance]Yahoo! Finance
- Immunovia Publishes Interim Report for January-March 2024 [Yahoo! Finance]Yahoo! Finance
- Immunovia Publishes Interim Report for January-March 2024 [Yahoo! Finance]Yahoo! Finance
- Immunovia Publishes Full Year Report for 2023 [Yahoo! Finance]Yahoo! Finance
ONCO
Sec Filings
- 5/15/24 - Form NT
- 5/13/24 - Form 8-K
- 4/26/24 - Form S-1/A
- ONCO's page on the SEC website